Kris Mahadeo, MD
Disclosures: Nothing to disclose
OMB No. 0925-0046, Biographical Sketch Format Page

OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: Kris Michael Mahadeo MD, MPH

eRA COMMONS USER NAME (credential, e.g., agency login):Krismd03

POSITION TITLE: Associate Professor

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

Adelphi University Honors College,

Garden City, NY

BS

1999

Biology

University of Medicine Dentistry New Jersey, Piscataway, NJ

        MPH

2009

Epidemiology

St. George’s University School of Medicine,                  Grenada, WI

MD

2003

Medicine

Children’s Hospital at Maimonides Medical   Center Pediatrics, Brooklyn, NY

 

2005

Pediatrics Internship

Children’s Hospital at St. Peter’s University Hospital Pediatrics, New Brunswick, NJ

 

2007

Pediatrics Residency

Children’s Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY

 

2010

Pediatric Hematology/Oncology Fellowship

Duke University Medical Center, Durham, NC

 

2011

Pediatric Blood & Marrow Stem Cell Transplantation Fellowship

A.              Personal Statement

As the Section Chief for Pediatrics Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, I lead the combined clinical and research operations and vision for the program.  This encompasses oversight for stem cell transplantation as well as immune effector cellular therapies.  I have formal training in clinical trials as part of a Master’s in Public Health degree and experience as a principal investigator for clinical trials involving cellular therapy. As an inspector for the Foundation for the Accreditation of Cellular Therapy (FACT) and former Director of Quality Management for the Blood and Marrow Transplant Program and Stem Cell Processing Laboratory at the Children’s Hospital Los Angeles (CHLA) I have added experience in regulatory compliance, data assurance and patient safety, especially as this relates to cellular therapy.  As the co-chair of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI)-Hematopoietic Stem Cell Therapy sub-group, my academic interests focus on reducing toxicity, improvement of supportive care strategies and critical care management, associated with cellular therapies for advanced malignancies.

 

B.              Positions and Honors

 

Positions and Employment

2011-2014              Assistant Professor, Clinical Pediatrics, University of Southern California Keck School of Medicine and Children’s Hospital Los Angeles, Los Angeles, CA

2012-2014              Director, Quality Management, Division of Hematology, Oncology and Blood & Marrow Transplantation Clinical Program, Children’s Hospital Los Angeles, Los Angeles, CA

2012-2014                            Director, Quality Management, Stem Cell Processing Laboratory, Children’s Hospital Los Angeles,

Los Angeles, CA

2012-present              Inspector, Foundation for the Accreditation of Cellular Therapy (FACT)

2014-2017                            Assistant Professor, Clinical Pediatrics, Albert Einstein College of Medicine, Bronx, NY

2014-2017              Director, Blood and Marrow Transplantation Program, Division of Hematology, Oncology, Children’s    Hospital at Montefiore, Bronx, NY

2016-present              Executive Committee, Pediatric Acute Lung and Sepsis Investigators: HSCT Subgroup

2017-present              Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

2017-present              Section Chief and Medical Director, Pediatric Stem Cell Therapy/Cell Therapy, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas, MD Anderson Cancer Center, Houston, TX

Honors

1995-1999                              Honors College Scholar, Adelphi University, Garden City, NY

1997                             Academic Achievement Award Scholar, Adelphi University, Garden City, NY

1998                  Outstanding Junior, Adelphi University, Garden City, NY

1998-1999         Honors College Honor Roll for Extraordinary Academic Achievement, Adelphi University, Garden City, NY

1999                  Who’s Who Among Students in American Colleges and Universities

2006                  “Best Inpatient Manager,” St. Peter’s University Hospital, New Brunswick, NJ

2010                  American Society of Clinical Oncology (ASCO) Travel Award

 

Professional Society Memberships

2008-2010        American Society of Pediatric Hematology Oncology

2008-present    American Society of Hematology

2011-present    Foundation for the Accreditation of Cellular Therapy

2012-present    Infectious Disease Society of America

2013-present    International Society for Cellular Therapy

2013-present    Pediatric Acute Lung and Sepsis Investigators

 

Professional Committee Memberships

2010-2011                     Member, Institutional Review Board (IRB), Duke University Medical Center, Durham, NC

2011-2014                     Member, Performance Improvement Committee, Bone Marrow Transplantation (BMT) Program, Children’s Hospital Los Angeles (CHLA), Los Angeles, CA

2014-2017              Member, Medical Advisory Committee, Montefiore Medical Center, Bronx, N.Y.

2016-2017              Member, Protocol Review and Monitoring Committee, Albert Einstein Cancer Center, Bronx, N.Y.

2017-present              Member, CARTOX Clinical Committee (Immune Effector Cell Program), The University of Texas, MD Anderson Cancer Center, Houston, TX

2017-present              Member, Quality Management Committee, Immune Effector Cell Program, The University of Texas, MD Anderson Cancer Center, Houston, TX

C.              Contributions to Science

Stem cell transplantation and cellular therapies for children with malignant diseases improve survival but have been associated with significant toxicity.  With improvement in treatment approaches and advances in critical care support, survival has improved.  Knowledge gaps regarding prognostication and optimal supportive strategies for this patient group has been an important focus.

 

Rowan CM, Gertz SJ, McArthur J, Fitzgerald JC, Nitu ME, Loomis A, Hsing DD, Duncan CN, Mahadeo KM, Smith LS, Moffet J, Hall MW, Pinos EL, Cheifetz IM, Tamburro RF. Invasive Mechanical Ventilation and Mortality in Pediatric Hematopoietic Stem Cell Transplantation: A Multicenter Study. Pediatr Crit Care Med 17(4):294-302, 4/2016.

PMID: 26910477.

 

Rowan CM, Smith LS, Loomis A, McArthur J, Gertz SJ, Fitzgerald JC, Nitu ME, Moser EA, Hsing DD, Duncan

CN, Mahadeo KM, Moffet J, Hall MW, Pinos EL, Tamburro RF, Cheifetz IM. Pediatric Acute Respiratory

Distress Syndrome in Pediatric Allogeneic Hematopoietic Stem Cell Transplants: A Multicenter Study. Pediatr

Crit Care Med 18(4):304-309, 4/2017.

PMID: 28178076.

 

 

Bajwa RPS*1, Mahadeo KM*1, Taragin BH, Dvorak CC, McArthur J, Jeyapalan A, Duncan CN, Tamburro R, Gehred A, Lehmann L, Richardson P, Auletta JJ, Woolfrey AE.  Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment.  Biol Blood Marrow Transplant. 2017 Nov;23(11):1817-1825.

PMID:  28754544

 

 

 

Mahadeo KM, McArthur J, Adams RH, Radhi M, Angelo J, Jeyapalan A, Nicol K, Su L, Rabi H, Auletta JJ, Pai

V, Duncan CN, Tamburro R, Dvorak CC, Bajwa RPS.  Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplant Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents: Part 2-Focus on Ascites, Fluid and Electrolytes, Renal, and Transfusion Issues.  Biol Blood Marrow Transplant. 2017 Aug 17. pii: S1083-8791(17)30649-3. PMID: 28823876.

 

Ovchinsky N, Frazier W, Auletta JJ, Dvorak CC, Ardura M, Song E, McArthur J, Jeyapalan A, Tamburro R, Mahadeo KM, Traube C, Duncan CN, Bajwa RPS.  Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 3: Focus on Cardiorespiratory Dysfunction, Infections, Liver Dysfunction, and Delirium.  Biol Blood Marrow Transplant. 2017 Sep 1. pii: S1083-8791(17)30690-0. PMID:28870776

 

Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.  Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.  Nat Rev Clin Oncol. 2018 Aug 6. doi: 10.1038/s41571-018-0075-2. [Epub ahead of print] Review. 

PMID: 30082906

 

 

As a member of the laboratory that identified the proton-coupled folate transported (PCFT) as the genetic basis for hereditary folate malabsorption, I worked with pediatricians to identify novel mutations that led to clinical manifestations of this disease. This work led to recognition of populations at disproportionately higher risk for this disease.  The role of this transporter in cancer predisposition and response to anti-folate therapies was also explored.

 

Atabay B, Turker M, Ozer EA, Mahadeo K, Diop-Bove N, Goldman ID. Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption. Pediatr Hematol Oncol 27(8):614-9, 11/2010.

PMCID: PMC3885236.

 

Mahadeo K, Diop-Bove N, Shin D, Unal ES, Teo J, Zhao R, Chang MH, Fulterer A, Romero MF, Goldman ID. Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. Am J Physiol Cell Physiol 299(5):C1153-61, 11/2010. e-Pub 8/2010.

PMCID: PMC2980313.

 

Shin DS, Mahadeo K, Min SH, Diop-Bove N, Clayton P, Zhao R, Goldman ID. Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Mol Genet Metab 103(1):33-7, 5/2011. e-Pub 1/2011.

PMCID: PMC3081934.

 

Mahadeo KM, Diop-Bove N, Ramirez SI, Cadilla CL, Rivera E, Martin M, Lerner NB, DiAntonio L, Duva S, Santiago-Borrero PJ, Goldman ID. Prevalence of a loss-of-function mutation in the proton-coupled folate transporter gene (PCFT-SLC46A1) causing hereditary folate malabsorption in Puerto Rico. J Pediatr 159(4):623-7.e1, 10/2011. e-Pub 4/2011.

PMCID: PMC3935241.

 

Lympho-depletion strategies have been integral to several HSCT protocols.   An understanding of immune homeostasis and restoration following HSCT informs emerging immune effector cell platforms. Future strategies will incorporate knowledge regarding recipient-host interactions and immune reconstitution kinetics following lympho-depletion.  This should lead to optimization of lympho-depletion strategies and timing of immune effector cell administration in relation to other backbone therapies.  

 

Reiff A, Weinberg KI, Triche T, Masinsin B, Mahadeo KM, Lin CH, Brown D, Parkman R. T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol 149(1):146-55, 10/2013. e-Pub 8/2013.

PMID: 23994768.

 

Mahadeo KM, Masinsin B, Kapoor N, Shah AJ, Abdel-Azim H, Parkman R. Immunologic resolution of human chronic graft-versus-host disease. Biol Blood Marrow Transplant 20(10):1508-15, 10/2014. e-Pub 6/2014.

PMID: 24979733.

 

Abdel-Azim H, Elshoury A, Mahadeo KM, Parkman R, Kapoor N. Humoral Immune Reconstitution Kinetics Following Allogeneic Hematopoietic Stem Cell Transplantation in Children: a Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. Biol Blood Marrow Transplant. e-Pub 5/2017.

PMID: 28495643.

 

 

Novel HSCT preparative regimens and alternative donor sources may improve access to HSCT and reduce associated toxicity.  Through multi-center and cross-discipline collaborations, we have published novel protocols for management of malignant and non-malignant diseases.  In some instances, small series are being further investigated among larger cohorts. 

 

Mahadeo KM, Weinberg KI, Abdel-Azim H, Miklos DB, Killen R, Kohn D, Crooks GM, Shah AJ, Kharbanda S, Agarwal R, Kapoor N.  A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor.  Biol Blood Marrow Transplant. 2015 Mar;21(3):440-4. doi: 10.1016/j.bbmt.2014.11.005. Epub 2014 Nov 13. 

PMID:  25459642

 

 

Abdel-Azim H, Jovi-Usude B, Balian C, Shah AJ, Tang S, Sinha A, Kapoor N, Mahadeo KM. Successful bone marrow transplantation of an adolescent young adult female with pregnancy-associated aplastic anemia.  J Pediatr Hematol Oncol. 2015 May;37(4):319-21.

PMID:  25774494.

 

Mehta B, Mahadeo K, Kapoor N, Abdel-Azim H.  Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease.  Pediatr Transplant. 2015 Jun;19(4):408-12. doi: 10.1111/petr.12471. Epub 2015 Apr 2.  PMID:  25845644

 

Abdel-Azim H, Kapoor N, Mahadeo KM, Finlay JL.  Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma.  Pediatr Blood Cancer. 2015 Sep;62(9):1667-9. doi: 10.1002/pbc.25525. Epub 2015 Apr 20. PMID: 25894457

 

Zhao Q, Mahadeo KM, Kapoor N, Abdel-Azim H.  Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia.  Blood. 2015 Jul 23;126(4):561-2.

PMID: 26206948

 

Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM, Shah AJ, Kapoor N.  Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. Am J Hematol. 2015 Nov;90(11):1021-6. doi: 10.1002/ajh.24141. Epub 2015 Oct 12. 

PMID: 26242764

 

Mahadeo KM, Tewari P, Parikh SH, Driscoll TA, Page K, Martin PL, Kurtzberg J, Prasad VK.  Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation.  Pediatr Transplant. 2015 Nov;19(7):753-7. doi: 10.1111/petr.12577. Epub 2015 Sep 14. 

PMID:  26369627

 

Polishchuk V, Khazal S, Berulava G, Roth M, Mahadeo KM5-Azacitidine Monotherapy Followed by Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient With Acute Undifferentiated Leukemia Refractory to High-Dose Chemotherapy.  Pediatr Blood Cancer. 2016 Jun;63(6):1111-2. Epub 2016 Feb 23. 

PMID:  26914221

 

Khazal S, Polishchuk V, Manwani D, Gallagher PG, Prinzing S, Mahadeo KM. Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency.  Blood. 2016 Aug 4;128(5):735-7. Epub 2016 Jun 13. No abstract available.  

PMID: 27297791

 

D.              Research Support

Ongoing Research Support:

 

Atara Biotherapeutics, Inc.                                                                                Willis Navarro (PI)                2018-present

Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable Options

The primary objective of this protocol is to provide access to EBV-CTLs to patients with EBV-associated malignancies (as listed below), for whom there are no other satisfactory therapeutic options, and who are not eligible to enroll in clinical trials designed to support the development and registration of EBV-CTLs.

Role: Institutional Principal Investigator

 

Atara Biotherapeutics, Inc.                                                                                Willis Navarro (PI)                2018-present

Multicenter, Open-Label, Phase 3 Trial of ATA129 for Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab (MATCH Study)

The primary objective is to determine the clinical benefit of ATA129 in subjects with EBV-PTLD after failure of rituximab.

Role: Institutional Principal Investigator

 

 

Atara Biotherapeutics, Inc.                                                                                Willis Navarro (PI)                       2018-present

Multicenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects with

Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of

Rituximab or Rituximab and Chemotherapy (ALLELE Study)

The primary objective is to determine the clinical benefit of ATA129 (third-party donor-derived allogeneic Epstein-

Barr virus specific cytotoxic T lymphocytes [EBV-CTLs]) in solid organ transplant (SOT) subjects with

EBV-associated post-transplant lymphoproliferative disease (EBV-PTLD) after failure of rituximab or rituximab

plus chemotherapy, as measured by the objective response rate (ORR),Role: Institutional Principal Investigator

 

 

Gamida Cell Ltd.                                                                                                                                                                                                     Joanne Kurtzberg  (PI)                2018-present

Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies

The primary objective is to assess (i) acute toxicity associated with the infusion of NiCord®, within 24 hours post-infusion and (ii) cumulative incidence of donor-derived neutrophil engraftment by day 42 following transplantation of NiCord®

 

Completed Research Support

 

Postdoctoral Fellow, 100%, Proton Coupled Folate Transporter and Chemotherapy, St. Baldrick's Foundation, 7/2009-9/2011, $135,000

Postdoctoral Fellow, 100%, Congenital amegakaryocytic thrombocytopenia and umbilical cord blood transplantation, NIH5 T32 CA 74736-10, NIH/NCI, 7/2010-6/2011, $67,500

Principal Investigator, 5%, Phase 3, Open-label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMXOO l) for the Prevention of Adenovirus (AdV) Disease in Subjects at with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated Adenovirus Disease, Chimerix, Inc, 2/2015-5/2016, $368,108

Principal Investigator, 5%, A Multicenter Non-Interventional Study to Obtain Retrospective Data for Subjects Previously Diagnosed with Adenovirus Infection to serve as Matched Historical Controls for Study CMXOO l -304, Chimerix, Inc, 10/2015-5/2016, $48,374

Principal Investigator, 5%, MSB-GVHDOO l : A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells, for the Treatment of Pediatric Patients who Have Failed to Respond to Steroid Treatment for Acute GVHD, Mesoblast, 2015-2017, $350,000

Principal Investigator, Safety Follow-up Through 180 days of Treatment with Remestemcel-L in Study MSBGVHD001 in Pediatric Patients who Have Failed to Respond to Steroid Treatment for Acute GVHD, Mesoblast, 2015-2017, $18,500